Third Party Payer Guidelines 11.2019
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 1511 - 1520 ntawm 4179
Tus kws kho mob
BCBSMN-Upcoming-Pharm-Policy-Notif-040121.pdf
Tus kws kho mob
Disclosure of Ownership and Management Information Form
Tus kws kho mob
QP16-21 Overpayment Refund/Recoupment Notification Process for Minnesota Health Care Programs
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP15-21 Provider Fee Schedule Request
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP14-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Enspryng™(satralizumab-mwge) PAQL
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP13-21 Commercial and MHCP Pharmacy Benefit Exclusion for Cabenuva
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP9-21 New Request Form for Medical Policy Coverage Exception Requests for Commercial Members
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP11-21 Commercial Pharmacy Benefit Exclusion for Select Medications
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021
Tus kws kho mob
QP10-21 Commercial Pharmacy Benefit Exclusion for Emtricitabine-Tenofovir Disoproxil Fumarate Tablet 100-150 mg, 133-200 mg, and 167-250 mg
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 10, 2021